Courtesy- Shuttershock
US-based molecular diagnostics firm Myriad Genetics has introduced a new medical tool, riskScore, to support its myRisk test developed for hereditary cancer.
riskScore is an algorithm designed to combine genetic markers with a patient’s family and clinical history to quantify the risk of breast cancer development.
The tool will combine data from more than 80 genetic markers called single nucleotide polymorphisms (SNPs) throughout the genome with a family and personal history algorithm called Tyrer-Cuzick model.
The Myriad myRisk Hereditary Cancer test is a 28-gene panel that can identify the risk of breast, ovarian, gastric, colorectal, pancreatic, melanoma, prostate and endometrial cancers.
In addition to a risk assessment, the simple and easy-to-use test delivers specific medical management recommendations to patients who test either positive or negative according to the guidelines of select professional medical societies.
